{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:43Z","timestamp":1785466723956,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005611","name":"University of Fukui","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005611","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12328-026-02336-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:46:02Z","timestamp":1777275962000},"page":"751-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4952-8714","authenticated-orcid":false,"given":"Kazuto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-3555","authenticated-orcid":false,"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2336_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"2336_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"2336_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"2336_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","volume":"31","author":"K Shitara","year":"2025","unstructured":"Shitara K, Janjigian YY, Ajani J, et al. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat Med. 2025;31:1519\u201330.","journal-title":"Nat Med"},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u201358.","journal-title":"Nat Med"},{"key":"2336_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","volume":"19","author":"K Masuda","year":"2019","unstructured":"Masuda K, Shoji H, Nagashima K, Yamamoto S, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974.","journal-title":"BMC Cancer"},{"key":"2336_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11523-021-00790-w","volume":"16","author":"Y Kono","year":"2021","unstructured":"Kono Y, Choda Y, Nakagawa M, et al. Association between immune-related adverse events and the prognosis of patients with advanced gastric cancer treated with nivolumab. Target Oncol. 2021;16:237\u201348.","journal-title":"Target Oncol"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"1408755","DOI":"10.3389\/fonc.2024.1408755","volume":"14","author":"YJ Zhang","year":"2024","unstructured":"Zhang YJ, Tian QY, Wang CE. Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis. Front Oncol. 2024;14:1408755.","journal-title":"Front Oncol"},{"key":"2336_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"2336_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, et al. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018;124:1111\u201321.","journal-title":"Cancer"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"1503316","DOI":"10.3389\/fimmu.2024.1503316","volume":"15","author":"T Zhang","year":"2024","unstructured":"Zhang T, Lv H, Li J, Zhang S, et al. The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment. Front Immunol. 2024;15:1503316.","journal-title":"Front Immunol"},{"key":"2336_CR14","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","volume":"25","author":"G Wan","year":"2024","unstructured":"Wan G, Chen W, Khattab S, et al. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol. 2024;25:1053\u201369.","journal-title":"Lancet Oncol"},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"107327482211305","DOI":"10.1177\/10732748221130576","volume":"29","author":"H Hata","year":"2022","unstructured":"Hata H, Matsumura C, Chisaki Y, et al. A retrospective cohort study of multiple immune-related adverse events and clinical outcomes among patients with cancer receiving immune checkpoint inhibitors. Cancer Control. 2022;29:10732748221130576.","journal-title":"Cancer Control"},{"key":"2336_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879900","volume":"13","author":"X Xie","year":"2022","unstructured":"Xie X, Wang L, Li Y, et al. Multi-organ Immune-Related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study. Front Immunol. 2022;13:879900.","journal-title":"Front Immunol"},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"21666","DOI":"10.1002\/cam4.6724","volume":"12","author":"Y Tasaki","year":"2023","unstructured":"Tasaki Y, Sugiyama Y, Hamamoto S, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: a retrospective multidisciplinary study. Cancer Med. 2023;12:21666\u201379.","journal-title":"Cancer Med"},{"key":"2336_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329\u201338.","journal-title":"Gastric Cancer"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02336-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:03:39Z","timestamp":1785463419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02336-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02336-x","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient included in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its subsequent amendments.","order":3,"name":"Ethics","label":"Human rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}